BCBS Tennessee Medical Policy Updates – August 2018

Click here to view the Blue Cross Blue Shield Tennessee Medical Policy Updates »

August 2018 BCBS Tennessee Medical Policy Updates:

• Abatacept
• Abatacept
• Ablation Procedure for Peripheral Neuromas
• AbobotulinumtoxinA
• Bariatric Surgery
• Bendamustine HCl (Bendeka®)
• Bendamustine HCl (Treanda®)
• Brachytherapy and Accelerated Partial Breast Irradiation for Breast Cancer
• Cardioverter Defibrillators
• Carfilzomib
• Certolizumab Pegol
• Cervical Traction Devices for Home Use
• Computed Tomography to Detect Coronary Artery Calcification (i.e., calcium scoring)
• Cryosurgical Ablation for the Treatment of Prostate Tumors
• Electronic Brachytherapy for Non-Melanoma Skin Cancer
• Fluocinolone Acetonide Intravitreal Implant for the Treatment of Uveitis
• Galsulfase
• Gender Reassignment Surgery
• Gene Expression Profile Analysis for Prostate Cancer Management
• Genetic Testing for Cutaneous Malignant Melanoma
• Genetic Testing for Dilated Cardiomyopathy
• Genetic Testing for Mental Health Conditions
• Genetic Testing for the Diagnosis of Inherited Peripheral Neuropathies
• Genotyping for Chronic Hepatitis C
• Hematopoietic Stem Cell Transplantation for Autoimmune Diseases
• Hematopoietic Stem Cell Transplantation in the Treatment of Germ Cell Tumors
• Idursulfase
• Immune Cell Function Assay
• IncobotulinumtoxinA
• Infliximab-abda
• Infliximab-dyyb
• Intraoperative Radiation Therapy (IORT)
• Ipilimumab
• Manipulation Under Anesthesia (MUA) of the Musculoskeletal System
• Measurement of Serum Antibodies to Infliximab and Adalimumab
• Methoxy Polyethylene Glycol-Epoetin Beta
• Microwave Ablation for Oncologic Tumors
• Nivolumab
• Non-Contact Ultrasound Treatment for Wounds
• Non-invasive Prenatal Testing Using Cell-free Fetal DNA (cffDNA)
• Obinutuzumab
• Olaratumab
• OnabotulinumtoxinA
• Orthognathic Surgery
• Osteochondral Allografting
• Osteochondral Autografting (OCG)
• Ovarian Cancer Tumor Markers
• Pegademase Bovine
• Pegfilgrastim
• Pelvic Floor Stimulation
• Pertuzumab
• Quantitative Sensory Testing
• Ramucirumab
• RimabotulinumtoxinB
• Sargramostim
• Siltuximab
• Subcutaneous Immune Globulins
• Temozolomide for Injection
• Testosterone Pellets for Subcutaneous Implantation
• Tocilizumab (Intravenous)
• Tocilizumab (Intravenous)
• Transvaginal and Transurethral Radiofrequency Tissue Remodeling for Urinary Stress Incontinence
• Vedolizumab
• Voretigene Neparvovec-rzyl
• Vulvectomy
• Whole Exome and Genome Sequencing

Click here to view the Blue Cross Blue Shield Tennessee Medical Policy Updates »

Policy Alerts monitors Commercial and Medicare medical policies for changes. While medical Insurance carriers typically update medical policies annually, there are many reasons why they might review or update a policy. When reviews occur out of cycle they often go unnoticed. Policy Alerts keeps you updated when Payers make coverage changes to medical policies affecting your business.

Policy Alerts continuously monitors Commercial and Medicare Payer coverage information to keep you up-to-date on medical Insurance decisions in real-time. When changes occur, instant email alerts are delivered to your inbox. Clients have access to detailed coverage reports and medical policies through the interactive Policy Alerts Dashboard portal. Save time each month and keep focused on important Payer medical policy reviews and coverage decisions affecting your business!

Policy Alerts takes a client-focused hands-on approach and is constantly working to provide our customers with helpful insights and actionable analytics. We understand what our clients need and are dedicated to providing timely, accurate, and always up-to-date reports.

Health economic and reimbursement information provided by Policy Alerts is gathered from third-party sources and is subject to change without notice as a result of complex and frequently changing laws, regulations, rules and policies. All product and company names are trademarks™ or registered® trademarks of their respective holders. Use of them does not imply any affiliation with or endorsement by them. This information is presented for illustrative purposes only and does not constitute reimbursement or legal advice.